Viewing Study NCT03554395


Ignite Creation Date: 2025-12-24 @ 2:08 PM
Ignite Modification Date: 2026-01-04 @ 2:31 PM
Study NCT ID: NCT03554395
Status: WITHDRAWN
Last Update Posted: 2020-10-19
First Post: 2018-05-31
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Gastric Cancer
Sponsor: Fuda Cancer Hospital, Guangzhou
Organization:

Study Overview

Official Title: Phase II Randomized Comparison Clinical Trial of Target Activated CIK for Advanced Gastric Cancer
Status: WITHDRAWN
Status Verified Date: 2020-05
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: No participants enrolled
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: This is a phase II Randomized comparison clinical trial of activated CIK armed with anti-CD3-MUC1 bispecific antibody for advanced gastric cancer. And the aim of this research is to study the clinical efficacy and safety of activated CIK armed with anti-CD3-MUC1 bispecific antibody for gastric cancer.
Detailed Description: Primary gastric carcinoma is one of the most common malignancies in China, Immunetherapy is considered to be one of the most promising means of human against cancer. This is a phase II clinical trial of single- center, The investigators plan to recruit for 90 patients with advanced gastric cancer,and all patients are divided into three groups.one group will receive cryotherapy, one group will receive conventional therapy,and the rest one will receive mixed liquor of activated CIK and anti-CD3-MUC1 bispecific antibody together with cryotherapy.

The result of this study was statistic and analysed with the record of Response Evaluation Criteria In Solid Tumors(RECIST1.1) evaluation standard.

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: